Sampling, identification and sensory evaluation of odors of a newborn baby’s head and amniotic fluid

For baby odor analyses, noninvasive, stress-free sample collection is important. Using a simple method, we succeeded in obtaining fresh odors from the head of five newborn babies. These odors were chemically analyzed by two-dimensional gas chromatography coupled with mass spectrometry (GC x GC-MS), and compared with each other or with the odor of amniotic fluid from the baby\u27s mother. We identified 31 chemical components of the volatile odors from neonate heads and 21 from amniotic fluid. Although 15 of these components were common to both sources, there was an apparent difference in the GC x GC patterns between the head and amniotic fluid odors, so the neonate head odor might be individually distinct immediately after birth. Therefore, we made artificial mixtures of the major odor components of the neonate head and maternal amniotic fluid, and used psychological tests to examine whether or not these odors could be distinguished from each other. Our data show that the artificial odor of a neonate head could be distinguished from that of amniotic fluid, and that the odors of artificial head odor mixtures could be correctly discriminated for neonates within an hour after birth and at 2 or 3 days of age

An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model

Abstract Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs, 60–70% of patients are still resistant to first-line cancer immunotherapy. In the present study, undertook combination immunotherapy for RCC using an oral cancer vaccine (Bifidobacterium longum displaying WT1 tumor associated antigen (B. longum 420)) with anti-PD-1 and anti-CTLA-4 antibodies in a mouse syngeneic model of RCC to explore possible synergistic effects. We found that B. longum 420 significantly improved the survival of mice bearing RCC tumors treated by anti-PD-1 and anti-CTLA-4 antibodies compared to the mice treated by the antibodies alone. This result suggests that B. longum 420 oral cancer vaccine as an adjunct to ICIs could provide a novel treatment option for RCC patients. Our microbiome analysis revealed that the proportion of Lactobacilli was significantly increased by B. longum 420. Although the detailed mechanism of action is unknown, it is possible that microbiome alteration by B. longum 420 enhances the efficacy of the ICIs